

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/010573-2026>

Tender

NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide

NHS England

UK4: Tender notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2026/S 000-010573

Procurement identifier (OCID): ocds-h6vhtk-051c39 ([view related notices](#))

Published 5 February 2026, 3:03pm

Scope

Reference

CM/PHG/24/5716

Description

NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.

Offer reference number: CM/PHG/24/5716

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Periods of call-offs under the framework agreement:

CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Commercial tool

Establishes a framework

Total value (estimated)

- £33,981,928 excluding VAT
- £40,778,314 including VAT

Above the relevant threshold

Contract dates (estimated)

- 1 June 2026 to 31 May 2028
- Possible extension to 31 May 2030
- 4 years

Description of possible extension:

option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.

Options

The right to additional purchases while the contract is valid.

option or options to extend (at the discretion of the Authority) for a period or periods up to

a total of 48 months.

Main procurement category

Goods

CPV classifications

- 33600000 - Pharmaceutical products

Contract locations

- UKC - North East (England)
 - UKD - North West (England)
 - UKE - Yorkshire and the Humber
 - UKF - East Midlands (England)
 - UKG - West Midlands (England)
 - UKH - East of England
 - UKI - London
 - UKJ - South East (England)
 - UKK - South West (England)
-

Lot 1. Lenalidomide

Description

Lenalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Lot value (estimated)

- £1 excluding VAT
- £1 including VAT

Framework lot values may be shared with other lots

Same for all lots

CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.

Lot 2. Pomalidomide

Description

Pomalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Lot value (estimated)

- £1 excluding VAT
- £1 including VAT

Framework lot values may be shared with other lots

Same for all lots

CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.

Lot 3. Thalidomide

Description

Thalidomide

CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028

NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028

LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028

Lot value (estimated)

- £1 excluding VAT
- £1 including VAT

Framework lot values may be shared with other lots

Same for all lots

CPV classifications, contract locations, contract dates and options are shown in the Scope section, because they are the same for all lots.

Framework

Maximum number of suppliers

Unlimited

Maximum percentage fee charged to suppliers

0%

Framework operation description

Please refer to the ITO Documents for the Operation Description

Award method when using the framework

With competition

Contracting authorities that may use the framework

Please refer to Document No. 09 in the

ITO Documents for the list of

Purchasing Points.

Participation

Particular suitability

Lot 1. Lenalidomide

Lot 2. Pomalidomide

Lot 3. Thalidomide

Small and medium-sized enterprises (SME)

Submission

Enquiry deadline

2 March 2026, 5:00pm

Tender submission deadline

9 March 2026, 1:00pm

Submission address and any special instructions

The procurement documents are

available for unrestricted and full direct

access, free of charge at <https://health-family.force.com/s/Welcome>

Additional information may be obtained
from the abovementioned address.

Tenders must be submitted to the
above mentioned address.

Tenders may be submitted electronically

Yes

Languages that may be used for submission

English

Award decision date (estimated)

16 March 2026

Award criteria

Lot 1. Lenalidomide

Name	Description	Type
Price	Price is not the only award criterion and all criteria are stated in the procurement documentation	Price

Weighting description

Price is not the only award criterion and all criteria are stated only in the procurement

documents.

Lot 2. Pomalidomide

Lot 3. Thalidomide

Name	Description	Type
Price	Price is not the only award criterion and all criteria are stated in the procurement documentation	Price

Weighting description

Price is not the only award criterion and all criteria are stated in the procurement documentation

Other information

Applicable trade agreements

- Government Procurement Agreement (GPA)

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Open procedure

Documents

Associated tender documents

[Tender Documents CM-PHG-24-5716.zip](#)

Contracting authority

NHS England

- Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Email: david.ford1@nhs.net

Website: <https://www.england.nhs.uk/>

Region: UKI45 - Lambeth

Organisation type: Public authority - central government